Literature DB >> 16881859

Assessment of the use of RNA quality metrics for the screening of articular cartilage specimens from clinically normal dogs and dogs with osteoarthritis.

Dylan N Clements1, Anne Vaughan-Thomas, Siriporn Peansukmanee, Stuart D Carter, John F Innes, William E R Ollier, Peter D Clegg.   

Abstract

OBJECTIVE: To assess 2 methods of RNA purification by use of different quality metrics and identify the most useful metric for quality assessment of RNA extracted from articular cartilage from dogs with osteoarthritis. SAMPLE POPULATION: 40 articular cartilage specimens from the femoral heads of 3 clinically normal dogs and 37 dogs with osteoarthritis. PROCEDURES: RNA was extracted from articular cartilage by 2 purification methods. Quality metrics of each sample were determined and recorded by use of a UV spectrophotometer (Spec I; to determine the 260 to 280 nm absorbance ratio [A(260):A(280) ratio]), a second UV spectrophotometer (Spec II; to determine A(260):A(280) and A(260):A(230) absorbance ratios), and a microfluidic capillary electrophoresis analyzer (to determine the ribosomal peak ratio [RR], degradation factor [DF], and RNA integrity number [RIN]). The RNA was extracted from affected (osteoarthritic) articular cartilage and assessed with the same quality metrics. Metric results were compared with visual analysis of the electropherogram to determine the most useful RNA quality metric.
RESULTS: No differences in methods of RNA purification were determined by use of quality metrics. The RNA extracted from unaffected (normal) cartilage was of higher quality than that extracted from affected (osteoarthritic) cartilage, as determined by the RIN and Spec II A(260):A(230) ratio. The RIN and RR were the most sensitive metrics for determining RNA quality, whereas the DF was most specific. A significant proportion (32%) of RNA extracted from osteoarthritic articular cartilage specimens was determined as being of low quality. CONCLUSIONS AND CLINICAL RELEVANCE: No single metric provided a completely sensitive and specific assessment of the quality of RNA recovered from articular cartilage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16881859     DOI: 10.2460/ajvr.67.8.1438

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

1.  Analysis of normal and osteoarthritic canine cartilage mRNA expression by quantitative polymerase chain reaction.

Authors:  Dylan N Clements; Stuart D Carter; John F Innes; William E R Ollier; Philip J R Day
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

2.  Optimizations for identifying reference genes in bone and cartilage bioengineering.

Authors:  Fei Xiong; Xiangyun Cheng; Chao Zhang; Roland Manfred Klar; Tao He
Journal:  BMC Biotechnol       Date:  2021-03-17       Impact factor: 2.563

3.  Histological and molecular characterisation of feline humeral condylar osteoarthritis.

Authors:  John M Ryan; B Duncan X Lascelles; Javier Benito; Jon Hash; Sionagh H Smith; David Bennett; David J Argyle; Dylan N Clements
Journal:  BMC Vet Res       Date:  2013-06-04       Impact factor: 2.741

4.  Gene expression markers of tendon fibroblasts in normal and diseased tissue compared to monolayer and three dimensional culture systems.

Authors:  Sarah E Taylor; Anne Vaughan-Thomas; Dylan N Clements; Gina Pinchbeck; Lisa C Macrory; Roger K W Smith; Peter D Clegg
Journal:  BMC Musculoskelet Disord       Date:  2009-02-26       Impact factor: 2.362

5.  Expression stability of commonly used reference genes in canine articular connective tissues.

Authors:  Duncan Ayers; Dylan N Clements; Fiona Salway; Philip J R Day
Journal:  BMC Vet Res       Date:  2007-05-07       Impact factor: 2.741

6.  Identification of new reference genes for the normalisation of canine osteoarthritic joint tissue transcripts from microarray data.

Authors:  Lindsey J Maccoux; Dylan N Clements; Fiona Salway; Philip J R Day
Journal:  BMC Mol Biol       Date:  2007-07-25       Impact factor: 2.946

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.